The potential for genomic stocks could be massive, according to Wood, who foresees a combination of artificial intelligence and gene editing allowing scientists to anticipate and cure diseases like sickle cell disease and diabetes."The biggest upside surprises are going to come from the genomic space, and that's because the convergence of DNA sequencing, artificial intelligence, and gene therapies are going to cure disease," Wood said. "We actually think the next 'FANG' [stocks] are in the genomic age." Precision BioSciences is a clinical-stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific, versatile platform designed with therapeutic safety, delivery, and control in mind. Using ARCUS, Precision is developing allogeneic CAR T and in vivo gene correction therapies for cancer and infectious diseases. I’ve been increasingly interested in learning more about the genomic industry. After Cathie Wood’s bullish call and increased investment in this industry, I figured it's time for me to do some research myself. In this video I break down Precision Biosciences (DTIL) and why I think it could be a good pick in this space.